To see all protocols that comply with the WHO Essential Medicine List 
  1. Home
  2. Haematology and BMT
  3. Leukaemias
  4. Acute lymphoblastic leukaemia

Acute lymphoblastic leukaemia MRD+ blinatumomab

 The following have occurred in patients receiving blinatumomab:
  • Cytokine Release Syndrome, which may be life-threatening or fatal
  • Neurological toxicities, which may be severe, life-threatening, or fatal
  • Reactivation of JC viral infection

Interrupt or discontinue blinatumomab as recommended if any of these adverse events occur.

Patients with leukaemia should be considered for inclusion into clinical trials. Link to ALLG website and ANZCTR website.

This protocol is based on limited evidence; please refer to the evidence section of this protocol for more information.

On this page
Expand all Collapse all Back to top
Drug Dose Route Day
Blinatumomab 28 micrograms * CIV over 24 hours 1 to 28

* Patients greater than or equal to 45 kg receive a fixed-dose and for patients less than 45 kg, the dose is calculated using the patient’s body surface area (BSA) at 15 micrograms/m2/day (not exceeding 28 micrograms/day). 

Duration:
42 days . A single cycle of treatment is 28 days (4 weeks) of continuous infusion. Each cycle of treatment is separated by a 14 day (2 week) treatment-free interval.
Cycles:
1 to 4. Patients may receive 1 cycle of induction followed by 3 additional cycles of consolidation treatment.
Notes:
  • Hospitalisation is recommended at a minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.
  • Blinatumomab preparation and administration can be complex.  It is important that the instruction for preparation and administration provided in the Product Information are strictly followed to minimise medication errors. 
  • Intrathecal chemotherapy prophylaxis is recommended before and during blinatumomab therapy to prevent central nervous system ALL relapse. 
Drug status:

Blinatumomab: (PBS authority)

Cost:
~ $81,420 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes antineoplastic drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au), MIMS Online and other sources. These costs are reviewed and updated on eviQ at 6 monthly intervals.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on 28 day month.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Day 1
Dexamethasone 20 mg (IV) 60 minutes before the start of treatment
Blinatumomab 28 micrograms (CIV over 24 hours) in sodium chloride 0.9% over 24 hours

as a continuous infusion
Day 2 to 28
Blinatumomab 28 micrograms (CIV over 24 hours) in sodium chloride 0.9% over 24 hours

as a continuous infusion

Notes:

  • Dexamethasone 20 mg should also be administered as a premedication when restarting an infusion after an interruption of 4 hours or more. 
  • Blinatumomab preparation and administration can be complex.  It is important that the instruction for preparation and administration provided in the Product Information are strictly followed to minimise medication errors. 
  • Hospitalisation is recommended at a minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.
  • Intrathecal chemotherapy prophylaxis is recommended before and during blinatumomab therapy to prevent central nervous system ALL relapse. 

Duration:
42 days . A single cycle of treatment is 28 days (4 weeks) of continuous infusion. Each cycle of treatment is separated by a 14 day (2 week) treatment-free interval.
Cycles:
1 to 4. Patients may receive 1 cycle of induction followed by 3 additional cycles of consolidation treatment.
Drug Dose Route Day
Blinatumomab 28 micrograms * CIV over 24 hours 1 to 28

* Patients greater than or equal to 45 kg receive a fixed-dose and for patients less than 45 kg, the dose is calculated using the patient’s body surface area (BSA) at 15 micrograms/m2/day (not exceeding 28 micrograms/day). 

Duration:
42 days . A single cycle of treatment is 28 days (4 weeks) of continuous infusion. Each cycle of treatment is separated by a 14 day (2 week) treatment-free interval.
Cycles:
1 to 4. Patients may receive 1 cycle of induction followed by 3 additional cycles of consolidation treatment.
Notes:
  • Hospitalisation is recommended at a minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.
  • Blinatumomab preparation and administration can be complex.  It is important that the instruction for preparation and administration provided in the Product Information are strictly followed to minimise medication errors. 
  • Intrathecal chemotherapy prophylaxis is recommended before and during blinatumomab therapy to prevent central nervous system ALL relapse. 
Drug status:

Blinatumomab: (PBS authority)

Cost:
~ $81,420 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes antineoplastic drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au), MIMS Online and other sources. These costs are reviewed and updated on eviQ at 6 monthly intervals.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on 28 day month.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many antineoplastic drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Day 1
Dexamethasone 20 mg (IV) 60 minutes before the start of treatment
Blinatumomab 28 micrograms (CIV over 24 hours) in sodium chloride 0.9% over 24 hours

as a continuous infusion
Day 2 to 28
Blinatumomab 28 micrograms (CIV over 24 hours) in sodium chloride 0.9% over 24 hours

as a continuous infusion

Notes:

  • Dexamethasone 20 mg should also be administered as a premedication when restarting an infusion after an interruption of 4 hours or more. 
  • Blinatumomab preparation and administration can be complex.  It is important that the instruction for preparation and administration provided in the Product Information are strictly followed to minimise medication errors. 
  • Hospitalisation is recommended at a minimum for the first 3 days of the first cycle and the first 2 days of the second cycle.
  • Intrathecal chemotherapy prophylaxis is recommended before and during blinatumomab therapy to prevent central nervous system ALL relapse. 

Duration:
42 days . A single cycle of treatment is 28 days (4 weeks) of continuous infusion. Each cycle of treatment is separated by a 14 day (2 week) treatment-free interval.
Cycles:
1 to 4. Patients may receive 1 cycle of induction followed by 3 additional cycles of consolidation treatment.
  • Minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL) in patients in complete haematological remission
Venous access

Central venous access device (CVAD) is required to administer this treatment.

Read more about central venous access device line selection
Premedication

The product information states that premedication is required for this treatment.

Please refer to the treatment schedule for suggested premedication regimen. This may be substituted to reflect institutional policy.
Emetogenicity LOW

Dexamethasone has been included as both an antiemetic and premedication for hypersensitivity in this protocol.

Ensure that patients also have sufficient antiemetics for breakthrough emesis:

Metoclopramide 10 mg three times a day when necessary (maximum of 30 mg/24 hours, up to 5 days) OR

Prochlorperazine 10 mg PO or 12.5 mg IV every 6 hours when necessary.

Read more about preventing antineoplastic induced nausea and vomiting
Cytokine Release Syndrome/Infusion Reactions

Potentially life-threatening cytokine release syndrome (CRS) have been reported in patients receiving blinatumomab. 

Infusion reactions have also occurred and may be clinically indistinguishable from manifestations of CRS.

Serious adverse events included pyrexia, asthenia, headache, hypotension, elevated liver enzymes, total bilirubin increased, and nausea. In some cases, disseminated intravascular coagulation, capillary leak syndrome, and haemophagocytic lymphohistiocytosis/macrophage activation syndrome have been reported in the setting of CRS.

Patients should be closely monitored for signs or symptoms of these events.

Management of CRS events may require either temporary interruption or discontinuation of blinatumomab.
Neurologic toxicity

Approximately 65% of patients experienced neurological toxicity. The most common neurological symptoms were headaches and tremor. Grade 3 or higher, including fatal neurological adverse events, included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders. The majority of events resolved and infrequently led to blinatumomab treatment discontinuation.

Patients receiving blinatumomab should be closely monitored for signs and symptoms of neurological toxicity. If symptoms are severe blinatumomab should be temporarily interrupted or discontinued.
Leukoencephalopathy

There is a potential risk of leukoencephalopathy in patients receiving blinatumomab. Cranial magnetic resonance imaging (MRI) changes showing leukoencephalopathy have been observed, especially in patients with prior treatment with cranial irradiation and anti-leukaemic chemotherapy (including systemic high dose methotrexate or intrathecal cytarabine).

The clinical significance of these imaging changes is unknown.
Progressive multifocal leukoencephalopathy

Use of monoclonal antibodies may be associated with an increased risk of progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal opportunistic viral infection of the brain. Patients must be monitored for any new or worsening neurological symptoms.

Read more about progressive multifocal leukoencephalopathy and the Therapeutic Goods Administration Medicines Safety update on progressive multifocal leukoencephalopathy from the Australian Government, Department of Health.
Pancreatitis

Pancreatitis, life-threatening or fatal, have been reported in patients receiving blinatumomab. In some cases, high-dose steroid therapy may have contributed. 

Monitor patients who develop signs and symptoms of pancreatitis, and if severe blinatumomab may be temporary interruption or discontinued.
Tumour lysis risk

Assess patient for risk of developing tumour lysis syndrome.

Read more about prevention and management of tumour lysis syndrome.
Pneumocystis jiroveci pneumonia (PJP) prophylaxis

PJP prophylaxis is recommended e.g. trimethoprim/sulfamethoxazole 160/800 mg PO one tablet twice daily, twice weekly (e.g. on Mondays and Thursdays) OR one tablet three times weekly (e.g. on Mondays, Wednesdays and Fridays).

Read more about prophylaxis of pneumocystis jiroveci (carinii) in cancer patients
Antiviral prophylaxis

­

Read more about antiviral prophylaxis drugs and doses
Antifungal prophylaxis ­

Read more about antifungal prophylaxis drugs and doses.
Irradiated blood components

Irradiation of blood components is recommended.

Read more about the indications for the use of irradiated blood components
Blood tests

FBC, EUC, LFTs, LDH, urate and lipase at baseline, then prior to each treatment or as clinically indicated
Hepatitis B screening and prophylaxis

Routine screening for HBsAg and anti-HBc is recommended prior to initiation of treatment. Prophylaxis should be determined according to individual institutional policy.

Read more about hepatitis B screening and prophylaxis in cancer patients requiring cytotoxic and/or immunosuppressive therapy
Vaccinations

Live vaccines, including BCG, MMR, zoster and varicella vaccines, are contraindicated in cancer patients receiving immunosuppressive therapy and/or who have poorly controlled malignant disease.

Refer to the recommended schedule of vaccination for immunocompromised patients, as outlined in the Australian Immunisation Handbook.
Effects of cancer treatment on fertility

Cancer treatment can have harmful effects on fertility and this should be discussed with all patients of reproductive age prior to commencing treatment.

Read more about the effect of cancer treatment on fertility
Evidence for dose modifications is limited, and the recommendations made on eviQ are intended as a guide only. They are generally conservative with an emphasis on safety. Any dose modification should be based on clinical judgement, and the individual patient’s situation including but not limited to treatment intent (curative vs palliative), the antineoplastic regimen (single versus combination therapy versus chemotherapy versus immunotherapy), biology of the cancer (site, size, mutations, metastases), other treatment related side effects, additional co-morbidities, performance status and patient preferences. Suggested dose modifications are based on clinical trial findings, product information and reference committee consensus. Non-haematological gradings are based on Common Terminology Criteria for Adverse Events (CTCAE) unless otherwise specified. Renal and hepatic dose modifications have been standardised where possible. For more information see dosing considerations & disclaimer.

Note: If there are interruptions in the treatment period due to adverse effects of:

  • Less than 7 days: continue the same cycle to a total of 28 days (inclusive of days before and after the interruption in that cycle)
  • Greater than 7 days: start a new cycle 

Dexamethasone 20 mg should also be administered as a premedication when restarting an infusion after an interruption of 4 hours or more. 

Haematological toxicity
There is no information regarding dose adjustment based on haematological parameters. Neutropenia and febrile neutropenia, including life threatening cases have been reported. Monitor FBC during blinatumomab administration and interrupt blinatumomab if prolonged neutropenia occurs. 
Renal impairment
There is no formal data in patients with renal impairment. However, based on pharmacokinetic analyses, dose adjustment in patients with mild to moderate renal impairment is not necessary. 
Hepatic impairment
There is no formal data in patients with hepatic impairment. Since blinatumomab is a protein and not metabolised through the hepatic pathway, dose adjustment is not necessary. 

 

Cytokine release syndrome (CRS)
Grade 3

Interrupt treatment until toxicity resolved. Then recommence at:

  • ≥ 45 kg: 9 micrograms/day. Escalate to 28 micrograms/day after 7 days if the toxicity does not recur.
  • < 45 kg: 5 micrograms/m2/day. Escalate to 15 micrograms/m2/day after 7 days if the toxicity does not recur.
Grade 4 Discontinue blinatumomab permanently
Neurological toxicity
Seizure Discontinue blinatumomab permanently if more than one seizure occurs
Grade 3

Interrupt treatment until toxicity has resolved to Grade 1 or less for at least 3 days. Then recommence at:

  • ≥ 45 kg: 9 micrograms/day. Escalate to 28 micrograms/day after 7 days if the toxicity does not recur.
    For reinitiation, premedication with 24 mg dexamethasone with a 4 day taper. As secondary prophylaxis, consider appropriate anticonvulsant medication.
    If the toxicity occurred at 9 micrograms/day, or if the toxicity takes >7 days to resolve discontinue blinatumomab permanently. 
  • < 45 kg: 5 micrograms/m2/day. Escalate to 15 micrograms/m2/day after 7 days if the toxicity does not recur.
    Consider appropriate anticonvulsant medication. If the toxicity occurred at
    5 micrograms/m2/day, or if the toxicity takes >7 days to resolve discontinue blinatumomab permanently. 
Grade 4 Discontinue blinatumomab permanently
Non-Haematological toxicity
Grade 3

Interrupt treatment until toxicity has resolved to Grade 1 or less. Then recommence at:

  • ≥ 45 kg: 9 micrograms/day. Escalate to 28 micrograms/day after 7 days if the toxicity does not recur.
  • < 45 kg: 5 micrograms/m2/day. Escalate to 15 micrograms/m2/day after 7 days if the toxicity does not recur.
Grade 4 Discontinue blinatumomab permanently

References & Disclaimer

Blinatumomab
No formal drug interaction studies have been conducted with blinatumomab. However blinatumomab is not expected to affect CYP450 enzyme activities.
General
  Interaction Clinical management
Warfarin Antineoplastic agents may alter the anticoagulant effect of warfarin. Monitor INR regularly and adjust warfarin dosage as appropriate; consider alternative anticoagulant.
Direct oral anticoagulants (DOACs) e.g. apixaban, rivaroxaban, dabigatran

Interaction with both CYP3A4 and P-gp inhibitors /inducers.

DOAC and antineoplastic levels may both be altered, possibly leading to loss of efficacy or toxicity (i.e. increased bleeding).

Apixaban: avoid concurrent use with strong CYP3A4 and P‑gp inhibitors. If treating VTE, avoid use with strong CYP3A4 and P‑gp inducers. 

Rivaroxaban: avoid concurrent use with strong CYP3A4 and P‑gp  inhibitors.

Dabigatran: avoid combination with strong P‑gp inducers and inhibitors.

If concurrent use is unavoidable, monitor closely for efficacy/toxicity of both drugs.
Digoxin Antineoplastic agents can damage the lining of the intestine; affecting the absorption of digoxin. Monitor digoxin serum levels; adjust digoxin dosage as appropriate.
Antiepileptics Both altered antiepileptic and antineoplastic levels may occur, possibly leading to loss of efficacy or toxicity. Where concurrent use of an enzyme-inducing antiepileptic cannot be avoided, monitor antiepileptic serum levels for toxicity, as well as seizure frequency for efficacy; adjust dosage as appropriate.
Also monitor closely for efficacy of the antineoplastic therapy.
Antiplatelet agents and NSAIDs Increased risk of bleeding due to treatment related thrombocytopenia. Avoid or minimise combination.
If combination deemed essential, (e.g. low dose aspirin for ischaemic heart disease) monitor for signs of bleeding.
Serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs e.g. paroxetine) and serotonin noradrenaline reuptake inhibitors (SNRIs e.g. venlafaxine) Increased risk of serotonin syndrome with concurrent use of 5-HT3 receptor antagonists (e.g. palonosetron, ondansetron, granisetron, tropisetron, dolasetron, etc.) Avoid combination.
If combination is clinically warranted, monitor for signs and symptoms of serotonin syndrome (e.g. confusion, agitation, tachycardia, hyperreflexia).
For more information link to TGA Medicines Safety Update
Vaccines Diminished response to vaccines and increased risk of infection with live vaccines. Live vaccines (e.g. BCG, MMR, zoster and varicella) are contraindicated in patients on immunosuppressive therapy. Use with caution in patients on non-immunosuppressive therapy.
For more information; refer to the recommended schedule of vaccination for cancer patients, as outlined in the Australian Immunisation Handbook

Note: Blinatumomab preparation and administration can be complex.  It is important that the instruction for preparation and administration provided in the Product Information are strictly followed to minimise medication errors. 

Day 1

General patient assessment prior to each day of treatment.

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Prime IV line(s).

Access CVC.

  • baseline weight
  • baseline neurological assessment e.g. daily handwriting assessment that includes the date, time and location. 

Pre treatment medication

Administer antiemetics if required

Dexamethasone

  • administer 60 minutes before the start of blinatumomab treatment 
  • administer via IV infusion over 15 minutes
  • flush with ~ 50mL sodium chloride 0.9%.

Blinatumomab

Prior to administration 
  • ensure a PVC-free line is used and primed with blinatumomab only and attach a protein-sparing 0.2 micron in-line filter  
  • dedicate a CVAD lumen solely for blinatumomab and ensure that no other drug or fluid is given through this port 
  • ensure that the infusion is commenced at an appropriate time to facilitate outpatient infusion bag / cassette changes. 
Administer blinatumomab  
  • via continuous IV infusion 
  • do not administer any remaining fluid once the prescribed infusion time has ceased as this may result in excess dosing
  • observe for signs of an infusion reaction especially cytokine release syndrome and/or neurological problems e.g. seizures,headache, confusion, slurred speech etc. 

If an infusion reaction occurs notify medical officer immediately 

  • for severe reactions stop infusion and manage as per emergency 

Note: do NOT flush the blinatumomab infusion line or the dedicated CVAD lumen, especially when changing infusion bags or cassettes. Flushing when changing bags or at completion of infusion can result in an excess dosage / drug bolus and complications to the patient. 

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Days 2 to 28

General patient assessment prior to each treatment.

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before recommencing treatment.

  • regular neurological assessment e.g. daily handwriting assessment that includes the date,time and location. 

Pre treatment medication

Administer antiemetics if required

Blinatumomab

Prior to administration 
  • ensure a PVC-free line is used and primed with blinatumomab only and attach a protein-sparing 0.2 micron in-line filter  
  • dedicate a CVAD lumen solely for blinatumomab and ensure that no other drug or fluid is given through this port 
  • ensure that the infusion is commenced at an appropriate time to facilitate outpatient infusion bag / cassette changes. 
Administer blinatumomab  
  • via continuous IV infusion 
  • do not administer any remaining fluid once the prescribed infusion time has ceased as this may result in excess dosing
  • observe for signs of an infusion reaction especially cytokine release syndrome and/or neurological problems e.g. seizures,headache, confusion, slurred speech etc. 

If an infusion reaction occurs notify medical officer immediately 

  • for severe reactions stop infusion and manage as per emergency 

Note: do NOT flush the blinatumomab infusion line or the dedicated CVAD lumen, especially when changing infusion bags or cassettes. Flushing when changing bags or at completion of infusion can result in an excess dosage / drug bolus and complications to the patient. 

Deaccess CVC.

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Discharge information

Antiemetics
  • Antiemetics as prescribed.
Prophylaxis medications
  • Prophylaxis medications (if prescribed) i.e. tumour lysis prophylaxis, PJP prophylaxis, antifungals, antivirals.
Patient information
  • Ensure patient receives patient information sheet.

The side effects listed below are not a complete list of all possible side effects for this treatment. Side effects are categorised into the approximate onset of presentation and should only be used as a guide.

Immediate (onset hours to days)
Hypersensitivity reaction

Anaphylaxis and infusion related reactions can occur with this treatment.

Read more about hypersensitivity reaction 
Nausea and vomiting

Read more about prevention of treatment induced nausea and vomiting
Flu-like symptoms

Early (onset days to weeks)
Fever
Headache
Neutropenia

Abnormally low levels of neutrophils in the blood. This increases the risk of infection. Any fever or suspicion of infection should be investigated immediately and managed aggressively. 

Read more about neutropenia
Thrombocytopenia

A reduction in the normal levels of functional platelets, increasing the risk of abnormal bleeding.  

Read more about thrombocytopenia
Diarrhoea

Read more about treatment induced diarrhoea
Hypokalaemia

Abnormally low levels of potassium in the blood.
Fluid retention and oedema

An excess amount of fluid around the cells, tissues or serous cavities of the body, leading to swelling.
Constipation
Fatigue

Read more about fatigue
Insomnia

Late (onset weeks to months)
Anaemia

Abnormally low levels of red blood cells (RBCs) or haemoglobin in the blood. 

Read more about anaemia
Cognitive changes (chemo fog)

Changes in cognition characterised by memory loss, forgetfulness and feeling vague. This is also referred to as 'chemo brain' or 'chemo fog'.

Read more about cognitive changes (chemo fog) 
Progressive multifocal leukoencephalopathy (PML)

A rare opportunistic viral infection of the brain, usually leading to death or severe disability, can occur with monoclonal antibodies (e.g. rituximab, obinutuzumab, ofatumumab, brentuximab vedotin) and other targeted therapies (e.g. ibrutinib, ruxolitinib, idelalisib). Onset may occur up to months after the final dose.  

Read more about progressive multifocal leukoencephalopathy (PML)

The main evidence supporting the use of blinatumomab in minimal residual disease (MRD) positive disease derives from a phase 2, open label, multicentre study.r

To be eligible, patients were required to be in complete haematological remission (CHR), defined as <5% blasts, neutrophil count >1.0 x 109/L, platelets >50000/uL and Hb >9 g/dL. They were required to have molecular failure with persistent or recurrent MRD >10-3 and to have received 3 blocks of high dose chemotherapy. Patients could be in their first or subsequent CHR.r

The main intention of the study was to determine the rates of conversion from MDR positivity to negativity, and to assess what affect conversion to MRD negativity had on overall outcomes.r

Given that this population of patients is expected to have substantially lower disease burden, there was no ramp up dosing in cycle 1, as there was in studies using blinatumomab in situations of frank relapsed or refractory disease. Corticosteroid pretreatment was given before each cycle to reduce risk of neurological events or cytokine release syndrome.r

Patients were given up to 4 cycles of blinatumomab, but could proceed to haematopoietic stem cell transplantation at any time after cycle 1. The primary endpoint was rate of MRD response after cycle 1. The key secondary end point was haematological RFS at 18 months after commencing blinatumomab.r

Source Study & Year Published Supports Use Is the dose and regimen consistent with the protocol? Comments
Phase II trials Gokbuget et al. 2018r Yes Yes -
Guidelines Date published/revised Supports Use Is the dose and regimen consistent with the protocol? Comments
NCCN Acute lymphoblastic leukaemia V1.2018 Yes Yes -
BCCA N/A N/A N/A -
CCO N/A N/A N/A -

Efficacy

113 patients were evaluable (59% male, 41% female). 88/113 (78%) achieved MRD negativity after cycle 1, 2 more patients after cycle 2 and then no further patients in cycle 3 or 4. In comparing MRD responders to non responders; RFS was 23.6 versus 5.7 months and OS was 38.9 versus 12.5 months.

Patients had better response rates if they were in their first CHR, compared with later CHRs, with median RFS of 24.6 versus 11.0 months respectively.r

Allogeneic transplantation

74/110 (67%) proceeded to allogeneic transplant. Of these, 36/74 (49%) were in CR at 2 years. This is compared with the 36/110 (33%) who did not go to allogenic transplantation, 9/36 (25%) were in CR at 2 years.r​

 

© Blood 2018

Toxicity

The most common adverse reactions among adult patients were pyrexia (89%), headache (38%), tremor (30%), chills (25.9%), fatigue (24.1%), nausea (23.3%), vomiting (22.4%), hypokalaemia (15.5%), and diarrhoea (19.8%). The most common grade 3 to 4 toxicities were neutropenia (17.2%) and pyrexia (7.8%).r

Patients with grade 4 neurologic events were required to permanently discontinue blinatumomab. 12/110 (10%) had >grade 3 events and required treatment interruption. 7 were able to resume at a lower dose, of whom 5 were able to continue at this dose. The other 2 stopped therapy in view of another neurological event. Tremor (5 pts), aphasia (3), seizure (3) and encephalopathy (3) were the commonest neurological events requiring treatment cessation.r​

© Blood 2018

[%id%]
[%title%]
[%abstract%]

Flinders Filters has partnered with eviQ to build reliable, robust search filters to retrieve core high level evidence on topics of significance to eviQ. The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content.

These search filters have been developed to retrieve the most up to date evidence from PubMed, in real time, using specifically designed search filters built to meet our needs.

Searches can be used when a protocol is scheduled for review or at any time you choose. Please click on the Specific, Balanced and Sensitive tabs below to access the Pubmed searches.

Specific Balanced Sensitive
restricted to retrieving randomised control trials and systematic reviews.

is the middle ground between sensitive and specific searches.

retrieves all clinically relevant evidence - generally a broader search on a given topic.

Access Flinders Filters, a division of the Flinders Digital Health Research Centre at Flinders University to read more about research solutions to searching problems.

Troubleshooting

Occasionally the searches may not display correctly or take too long to load (and will eventually timeout). This may be caused by Internet Explorer being unable to handle long URL's. You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.

Feedback

If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article(s). 

Version 1

Date Summary of changes
21/09/2018 New protocol taken to Haematology Reference Committee meeting
01/11/2018 New protocol published on eviQ. V1.
9/12/2019 PBS status updated to authority.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3483

12 Dec 2019